Comparison of baseline clinical and histological characteristics. Data are mean ± SD, except where otherwise indicated.
| Group | p | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| First biopsy | Proliferative or mixed | Proliferative or mixed | Membranous | Membranous | |
| Repeat biopsy | Proliferative or mixed | Membranous | Proliferative or mixed | Membranous | |
| Number of cases | 45 | 38 | 18 | 17 | |
| Age, yrs | 29.2 ± 11.4 | 29.2 ± 9.0 | 32.9 ± 10.5 | 31.9 ± 9.1 | 0.5 |
| Sex (M:F) | 3:42 | 5:33 | 1:17 | 2:15 | 0.7 |
| Duration of SLE, mo | 26.5 ± 34.6 | 27.6 ± 42.9 | 55.0 ± 55.2 | 36.0 ± 41.9 | 0.09 |
| Time between biopsies, mo | 30.9 ± 19.8 | 53.2 ± 44.7 | 60.7 ± 38.9 | 51.0 ± 44.7 | 0.007 |
| At time of first biopsy | |||||
| Creatinine, μmol/l | 129.5 ± 73.0 | 110.1 ± 41.9 | 111.2 ± 56.3 | 134.9 ± 103.7 | 0.4 |
| Proteinuria, g/day | 3.8 ± 2.2 | 4.4 ± 3.1 | 2.6 ± 1.3 | 3.9 ± 1.3 | 0.09 |
| GFR, ml/min/1.73m2 | 63.9 ± 37.5 | 68.2 ± 31.8 | 65.7 ± 26.3 | 65.0 ± 30.7 | 0.9 |
| SLEDAI | 10.4 ± 4.6 | 10.5 ± 3.4 | 10.1 ± 3.7 | 11.0 ± 4.4 | 0.9 |
| Therapy response (CR:PR:NR) | 18:26:1 | 24:13:1 | 9:7:2 | 6:8:3 | 0.06 |
| At time of second biopsy | |||||
| Creatinine, μmol/l | 164.6 ± 127.5 | 153.2 ± 128.6 | 170.2 ± 105.6 | 188.0 ± 271.8 | 0.9 |
| Proteinuria, g/day | 3.9 ± 2.9 | 2.9 ± 1.8 | 4.0 ± 2.5 | 4.3 ± 2.4 | 0.15 |
| GFR, ml/min/1.73m2 | 51.9 ± 28.3 | 60.0 ± 30.8 | 48.1 ± 31.5 | 68.3 ± 44.9 | 0.2 |
| SLEDAI | 9.2 ± 4.9 | 9.0 ± 4.3 | 11.1 ± 5.7 | 12.7 ± 2.6 | 0.02 |
| Therapy response (CR:PR:NR) | 17:21:7 | 21:11:6 | 3:13:2 | 4:6:7 | 0.008 |
SLE: systemic lupus erythematosus; GFR: glomerular filtration rate; SLEDAI: SLE Disease Activity Index; CR: complete response; PR: partial response; NR: no response.